Financial reports
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
10-K
2021 FY
Annual report
1 Mar 22
Current reports
8-K
Maravai Lifesciences Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
8-K
Maravai Lifesciences Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Maravai Lifesciences Reports Second Quarter 2023 Financial Results
7 Aug 23
8-K
Maravai LifeSciences Announces Completion of Planned CEO Leadership Transition
27 Jul 23
8-K
Maravai LifeSciences Announces Appointment of New Director to the Board
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
22 May 23
8-K
Maravai Lifesciences Reports First Quarter 2023 Financial Results
8 May 23
8-K
Departure of Directors or Certain Officers
13 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Maravai Lifesciences Reports Fourth Quarter and Full Year 2022 Financial Results
22 Feb 23
Registration and prospectus
424B4
Prospectus supplement with pricing info
13 Sep 21
S-1
IPO registration
7 Sep 21
DRS
Draft registration statement
26 Aug 21
424B4
Prospectus supplement with pricing info
9 Apr 21
S-1MEF
Registration of additional securities for an S-1
7 Apr 21
S-1/A
IPO registration (amended)
6 Apr 21
S-1
IPO registration
5 Apr 21
DRS
Draft registration statement
25 Mar 21
S-8
Registration of securities for employees
23 Nov 20
424B4
Prospectus supplement with pricing info
23 Nov 20
Proxies
Other
UPLOAD
Letter from SEC
28 Jul 22
CORRESP
Correspondence with SEC
12 Jul 22
UPLOAD
Letter from SEC
29 Jun 22
EFFECT
Notice of effectiveness
10 Sep 21
CORRESP
Correspondence with SEC
7 Sep 21
CORRESP
Correspondence with SEC
7 Sep 21
UPLOAD
Letter from SEC
31 Aug 21
EFFECT
Notice of effectiveness
8 Apr 21
CORRESP
Correspondence with SEC
5 Apr 21
CORRESP
Correspondence with SEC
5 Apr 21